Intrinsic value of Abiomed - ABMD

Previous Close

$144.10

  Intrinsic Value

$91.99

stock screener

  Rating & Target

sell

-36%

  Value-price divergence*

-12%

Previous close

$144.10

 
Intrinsic value

$91.99

 
Up/down potential

-36%

 
Rating

sell

 
Value-price divergence*

-12%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of ABMD stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 6.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2017(a)
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  34.85
  33.00
  30.20
  27.68
  25.41
  23.37
  21.53
  19.88
  18.39
  17.05
  15.85
  14.76
  13.79
  12.91
  12.12
  11.41
  10.76
  10.19
  9.67
  9.20
  8.78
  8.40
  8.06
  7.76
  7.48
  7.23
  7.01
  6.81
  6.63
  6.47
  6.32
Revenue, $m
  445
  592
  771
  984
  1,234
  1,522
  1,850
  2,218
  2,626
  3,074
  3,561
  4,086
  4,650
  5,250
  5,886
  6,557
  7,263
  8,003
  8,777
  9,585
  10,427
  11,303
  12,214
  13,162
  14,147
  15,170
  16,233
  17,339
  18,488
  19,683
  20,927
Variable operating expenses, $m
 
  467
  607
  775
  971
  1,197
  1,454
  1,742
  2,062
  2,413
  2,795
  3,204
  3,646
  4,116
  4,615
  5,141
  5,695
  6,275
  6,882
  7,515
  8,175
  8,862
  9,577
  10,319
  11,092
  11,894
  12,728
  13,594
  14,495
  15,432
  16,408
Fixed operating expenses, $m
 
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  5
  5
  5
  6
  6
  6
  6
  6
  6
Total operating expenses, $m
  355
  470
  610
  778
  974
  1,200
  1,457
  1,746
  2,066
  2,417
  2,799
  3,208
  3,650
  4,120
  4,619
  5,145
  5,699
  6,280
  6,887
  7,520
  8,180
  8,867
  9,582
  10,324
  11,097
  11,900
  12,734
  13,600
  14,501
  15,438
  16,414
Operating income, $m
  90
  122
  160
  206
  260
  322
  393
  472
  560
  657
  762
  879
  1,000
  1,130
  1,267
  1,412
  1,564
  1,724
  1,891
  2,065
  2,247
  2,436
  2,633
  2,837
  3,050
  3,271
  3,500
  3,739
  3,987
  4,245
  4,513
EBITDA, $m
  93
  127
  166
  212
  267
  330
  402
  482
  571
  669
  776
  891
  1,014
  1,145
  1,285
  1,432
  1,586
  1,748
  1,917
  2,094
  2,278
  2,470
  2,669
  2,877
  3,092
  3,316
  3,549
  3,791
  4,042
  4,304
  4,576
Interest expense (income), $m
  0
  1
  2
  3
  5
  7
  9
  11
  14
  17
  21
  24
  28
  33
  37
  42
  47
  53
  58
  64
  70
  77
  83
  90
  97
  105
  113
  121
  129
  138
  147
Earnings before tax, $m
  91
  121
  159
  203
  255
  316
  384
  461
  546
  640
  741
  854
  972
  1,097
  1,230
  1,370
  1,517
  1,671
  1,833
  2,001
  2,177
  2,359
  2,549
  2,747
  2,952
  3,166
  3,387
  3,618
  3,857
  4,107
  4,366
Tax expense, $m
  39
  33
  43
  55
  69
  85
  104
  124
  147
  173
  200
  231
  262
  296
  332
  370
  410
  451
  495
  540
  588
  637
  688
  742
  797
  855
  915
  977
  1,042
  1,109
  1,179
Net income, $m
  52
  88
  116
  148
  186
  230
  280
  337
  399
  467
  541
  624
  709
  801
  898
  1,000
  1,107
  1,220
  1,338
  1,461
  1,589
  1,722
  1,861
  2,005
  2,155
  2,311
  2,473
  2,641
  2,816
  2,998
  3,187

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  230
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  550
  425
  554
  707
  887
  1,094
  1,330
  1,594
  1,888
  2,210
  2,560
  2,938
  3,343
  3,774
  4,232
  4,714
  5,222
  5,754
  6,310
  6,891
  7,496
  8,126
  8,781
  9,462
  10,170
  10,906
  11,670
  12,465
  13,291
  14,151
  15,045
Adjusted assets (=assets-cash), $m
  320
  425
  554
  707
  887
  1,094
  1,330
  1,594
  1,888
  2,210
  2,560
  2,938
  3,343
  3,774
  4,232
  4,714
  5,222
  5,754
  6,310
  6,891
  7,496
  8,126
  8,781
  9,462
  10,170
  10,906
  11,670
  12,465
  13,291
  14,151
  15,045
Revenue / Adjusted assets
  1.391
  1.393
  1.392
  1.392
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
Average production assets, $m
  26
  34
  45
  57
  72
  88
  107
  129
  152
  178
  207
  237
  270
  304
  341
  380
  421
  464
  509
  556
  605
  656
  708
  763
  821
  880
  942
  1,006
  1,072
  1,142
  1,214
Working capital, $m
  257
  37
  49
  62
  78
  96
  117
  140
  165
  194
  224
  257
  293
  331
  371
  413
  458
  504
  553
  604
  657
  712
  770
  829
  891
  956
  1,023
  1,092
  1,165
  1,240
  1,318
Total debt, $m
  16
  47
  86
  132
  187
  250
  321
  401
  490
  588
  694
  808
  931
  1,062
  1,200
  1,346
  1,500
  1,661
  1,830
  2,006
  2,189
  2,380
  2,579
  2,785
  3,000
  3,222
  3,454
  3,695
  3,945
  4,206
  4,477
Total liabilities, $m
  98
  129
  168
  214
  269
  332
  403
  483
  572
  670
  776
  890
  1,013
  1,144
  1,282
  1,428
  1,582
  1,743
  1,912
  2,088
  2,271
  2,462
  2,661
  2,867
  3,082
  3,304
  3,536
  3,777
  4,027
  4,288
  4,559
Total equity, $m
  452
  297
  386
  493
  618
  763
  927
  1,111
  1,316
  1,540
  1,784
  2,048
  2,330
  2,631
  2,949
  3,286
  3,639
  4,010
  4,398
  4,803
  5,225
  5,664
  6,120
  6,595
  7,089
  7,601
  8,134
  8,688
  9,264
  9,863
  10,486
Total liabilities and equity, $m
  550
  426
  554
  707
  887
  1,095
  1,330
  1,594
  1,888
  2,210
  2,560
  2,938
  3,343
  3,775
  4,231
  4,714
  5,221
  5,753
  6,310
  6,891
  7,496
  8,126
  8,781
  9,462
  10,171
  10,905
  11,670
  12,465
  13,291
  14,151
  15,045
Debt-to-equity ratio
  0.035
  0.160
  0.220
  0.270
  0.300
  0.330
  0.350
  0.360
  0.370
  0.380
  0.390
  0.390
  0.400
  0.400
  0.410
  0.410
  0.410
  0.410
  0.420
  0.420
  0.420
  0.420
  0.420
  0.420
  0.420
  0.420
  0.420
  0.430
  0.430
  0.430
  0.430
Adjusted equity ratio
  0.694
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  52
  88
  116
  148
  186
  230
  280
  337
  399
  467
  541
  624
  709
  801
  898
  1,000
  1,107
  1,220
  1,338
  1,461
  1,589
  1,722
  1,861
  2,005
  2,155
  2,311
  2,473
  2,641
  2,816
  2,998
  3,187
Depreciation, amort., depletion, $m
  3
  5
  5
  6
  7
  8
  9
  10
  11
  12
  14
  12
  14
  16
  18
  20
  22
  24
  26
  29
  31
  34
  37
  40
  43
  46
  49
  52
  56
  59
  63
Funds from operations, $m
  61
  93
  121
  154
  193
  238
  289
  346
  410
  479
  555
  636
  723
  817
  915
  1,020
  1,129
  1,244
  1,364
  1,490
  1,620
  1,756
  1,898
  2,045
  2,198
  2,357
  2,522
  2,693
  2,872
  3,057
  3,250
Change in working capital, $m
  -16
  9
  11
  13
  16
  18
  21
  23
  26
  28
  31
  33
  35
  38
  40
  42
  44
  47
  49
  51
  53
  55
  57
  60
  62
  64
  67
  70
  72
  75
  78
Cash from operations, $m
  77
  84
  110
  141
  178
  220
  269
  323
  384
  451
  524
  603
  688
  779
  875
  977
  1,085
  1,198
  1,316
  1,439
  1,567
  1,701
  1,840
  1,985
  2,136
  2,292
  2,455
  2,624
  2,799
  2,982
  3,172
Maintenance CAPEX, $m
  0
  -1
  -2
  -2
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -11
  -12
  -14
  -16
  -18
  -20
  -22
  -24
  -26
  -29
  -31
  -34
  -37
  -40
  -43
  -46
  -49
  -52
  -56
  -59
New CAPEX, $m
  -16
  -8
  -10
  -12
  -15
  -17
  -19
  -21
  -24
  -26
  -28
  -30
  -33
  -35
  -37
  -39
  -41
  -43
  -45
  -47
  -49
  -51
  -53
  -55
  -57
  -59
  -62
  -64
  -67
  -69
  -72
Cash from investing activities, $m
  -58
  -9
  -12
  -14
  -18
  -21
  -24
  -27
  -31
  -34
  -37
  -41
  -45
  -49
  -53
  -57
  -61
  -65
  -69
  -73
  -78
  -82
  -87
  -92
  -97
  -102
  -108
  -113
  -119
  -125
  -131
Free cash flow, $m
  19
  74
  98
  126
  160
  200
  245
  296
  354
  417
  487
  562
  643
  730
  823
  921
  1,024
  1,133
  1,247
  1,366
  1,490
  1,619
  1,754
  1,894
  2,039
  2,190
  2,347
  2,511
  2,680
  2,857
  3,040
Issuance/(repayment) of debt, $m
  0
  32
  39
  46
  54
  63
  71
  80
  89
  98
  106
  115
  123
  131
  139
  146
  154
  161
  169
  176
  183
  191
  199
  206
  215
  223
  232
  241
  250
  260
  271
Issuance/(repurchase) of shares, $m
  11
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  7
  32
  39
  46
  54
  63
  71
  80
  89
  98
  106
  115
  123
  131
  139
  146
  154
  161
  169
  176
  183
  191
  199
  206
  215
  223
  232
  241
  250
  260
  271
Total cash flow (excl. dividends), $m
  26
  106
  137
  173
  215
  262
  316
  376
  443
  515
  593
  676
  766
  861
  961
  1,067
  1,178
  1,294
  1,415
  1,542
  1,673
  1,810
  1,952
  2,100
  2,254
  2,413
  2,579
  2,751
  2,931
  3,117
  3,311
Retained Cash Flow (-), $m
  -83
  -74
  -90
  -107
  -125
  -144
  -164
  -184
  -204
  -224
  -244
  -263
  -282
  -301
  -319
  -336
  -354
  -371
  -388
  -405
  -422
  -439
  -457
  -475
  -493
  -513
  -533
  -554
  -576
  -599
  -623
Prev. year cash balance distribution, $m
 
  229
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  262
  47
  66
  89
  118
  152
  192
  238
  290
  349
  413
  483
  560
  643
  731
  824
  923
  1,027
  1,137
  1,251
  1,371
  1,495
  1,625
  1,760
  1,900
  2,046
  2,198
  2,355
  2,518
  2,688
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  251
  43
  57
  73
  91
  110
  130
  149
  167
  183
  196
  206
  213
  216
  214
  209
  201
  189
  175
  159
  142
  124
  107
  90
  74
  60
  47
  36
  27
  20
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. It also manufactures and sells AB5000 circulatory support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, the company engages in the research, development, prototyping, and the pre-serial production of a percutaneous expandable catheter pump, which enhances blood circulation from the heart with an external drive shaft. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.

FINANCIAL RATIOS  of  Abiomed (ABMD)

Valuation Ratios
P/E Ratio 121
Price to Sales 14.1
Price to Book 13.9
Price to Tangible Book
Price to Cash Flow 81.7
Price to Free Cash Flow 103.2
Growth Rates
Sales Growth Rate 34.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 220%
Cap. Spend. - 3 Yr. Gr. Rate 39.8%
Financial Strength
Quick Ratio 230
Current Ratio 0
LT Debt to Equity 3.3%
Total Debt to Equity 3.5%
Interest Coverage 0
Management Effectiveness
Return On Assets 10.7%
Ret/ On Assets - 3 Yr. Avg. 20.9%
Return On Total Capital 12.4%
Ret/ On T. Cap. - 3 Yr. Avg. 24.5%
Return On Equity 12.7%
Return On Equity - 3 Yr. Avg. 24.6%
Asset Turnover 0.9
Profitability Ratios
Gross Margin 84.3%
Gross Margin - 3 Yr. Avg. 83.8%
EBITDA Margin 21.1%
EBITDA Margin - 3 Yr. Avg. 31.1%
Operating Margin 20.2%
Oper. Margin - 3 Yr. Avg. 30.1%
Pre-Tax Margin 20.4%
Pre-Tax Margin - 3 Yr. Avg. 30.1%
Net Profit Margin 11.7%
Net Profit Margin - 3 Yr. Avg. 24.3%
Effective Tax Rate 42.9%
Eff/ Tax Rate - 3 Yr. Avg. 28.7%
Payout Ratio 0%

ABMD stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ABMD stock intrinsic value calculation we used $445 million for the last fiscal year's total revenue generated by Abiomed. The default revenue input number comes from 2017 income statement of Abiomed. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ABMD stock valuation model: a) initial revenue growth rate of 33% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ABMD is calculated based on our internal credit rating of Abiomed, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Abiomed.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ABMD stock the variable cost ratio is equal to 79.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $3 million in the base year in the intrinsic value calculation for ABMD stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Abiomed.

Corporate tax rate of 27% is the nominal tax rate for Abiomed. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ABMD stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ABMD are equal to 5.8%.

Life of production assets of 19.3 years is the average useful life of capital assets used in Abiomed operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ABMD is equal to 6.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $452 million for Abiomed - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 43.532 million for Abiomed is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Abiomed at the current share price and the inputted number of shares is $6.3 billion.

RELATED COMPANIES Price Int.Val. Rating
TFX Teleflex 211.17 86.78  str.sell
DXTR Dextera Surgic 0.270 0.21  sell
ATRC AtriCure 23.74 0.47  str.sell
BSX Boston Scienti 27.62 19.06  sell
NSPR InspireMD 0.480 0.59  buy

COMPANY NEWS

▶ China, Medicals Lead Market; Why Apple Has Hit A Buy Point Now   [Jul-24-17 03:45PM  Investor's Business Daily]
▶ Abiomed Aims to Expand Impella RPs Penetration Going Forward   [Jul-21-17 04:35PM  Market Realist]
▶ Abiomed in 2017: The Analysts View   [Jul-20-17 05:47PM  Market Realist]
▶ ETFs with exposure to ABIOMED, Inc. : July 13, 2017   [Jul-13-17 03:21PM  Capital Cube]
▶ ETFs with exposure to ABIOMED, Inc. : June 30, 2017   [Jun-30-17 02:38PM  Capital Cube]
▶ 3 Growth Stocks for Daring Investors   [Jun-22-17 11:05AM  Motley Fool]
▶ ETFs with exposure to ABIOMED, Inc. : June 19, 2017   [Jun-19-17 02:49PM  Capital Cube]
▶ ETFs with exposure to ABIOMED, Inc. : May 31, 2017   [May-31-17 12:18PM  Capital Cube]
▶ Big-Cap Growth Fund, Up 15% In 2017, Recently Bought 3 IBD 50 Stocks   [May-26-17 08:05AM  Investor's Business Daily]
▶ Can This 2015 Medical IPO Inject New Life Into Its Stock?   [May-24-17 12:03PM  Investor's Business Daily]
▶ Abiomed, Inc. Pumps Out 33% Revenue Growth   [May-05-17 02:28PM  Motley Fool]
▶ Abiomed meets 4Q profit forecasts   [May-04-17 07:33AM  Associated Press]
▶ Diagnostic Kit Maker Tests Resistance In Base; Gets Rating Upgrade   [Apr-28-17 11:29AM  Investor's Business Daily]
▶ 3 Top Stocks to Buy With Your Tax Refund   [Apr-22-17 07:26AM  Motley Fool]
▶ Abiomed unveils expanded Danvers HQ as headcount soars   [Mar-30-17 07:19PM  at bizjournals.com]
▶ Abiomed unveils expanded Danvers HQ as headcount soars   [07:19PM  American City Business Journals]
▶ Has Masimo Become Too Expensive to Hold?   [Mar-20-17 07:09PM  Investopedia]
▶ Has Masimo Become Too Expensive to Hold?   [07:09PM  at Investopedia]
▶ 3 Most Wildly Overvalued Stocks in Healthcare   [Feb-24-17 09:24AM  at Motley Fool]
▶ Abiomed Celebrates 2017 American Heart Month   [12:06PM  GlobeNewswire]
▶ Today's Top 5 Stock Picks: Durable Growth   [Nov-23-16 07:48AM  at Barrons.com]
Stock chart of ABMD Financial statements of ABMD Annual reports of ABMD
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.